Usage Information

Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A.
R Glück, … , B Althaus, S J Cryz Jr
R Glück, … , B Althaus, S J Cryz Jr
Published December 1, 1992
Citation Information: J Clin Invest. 1992;90(6):2491-2495. https://doi.org/10.1172/JCI116141.
View: Text | PDF
Research Article Article has an altmetric score of 6

Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A.

Abstract

Hepatitis A virus (HAV) was purified from MRC-5 human diploid cell cultures, inactivated with formalin, and evaluated for safety and immunogenicity in humans. Three vaccine formulations were produced: (a) a fluid preparation containing inactivated HAV, (b) inactivated HAV adsorbed to Al(OH)3, and (c) inactivated HAV coupled to novel immunopotentiating reconstituted influenza virosomes (IRIV). IRIV were prepared by combining phosphatidylcholine, phosphatidylethanolamine, phospholipids originating from the influenza virus envelope, influenza virus hemagglutinin, and neuraminidase. The HAV-IRIV appeared as unilamellar vesicles with a diameter of approximately 150 nm when viewed by transmission electron microscopy. Upon intramuscular injection, the alum-adsorbed vaccine was associated with significantly (P < 0.01) more local adverse reactions than either the fluid or IRIV formulations. 14 d after a single dose of vaccine, all the recipients of the IRIV formulation seroconverted (> or = 20 mIU/ml) versus 30 and 44% for those who received the fluid and alum-adsorbed vaccines, respectively (P < 0.001). The geometric mean anti-HAV antibody titer achieved after immunization with the IRIV-HAV vaccine was also significantly higher (P < 0.005) compared with the other two vaccines.

Authors

R Glück, R Mischler, S Brantschen, M Just, B Althaus, S J Cryz Jr

×

Usage data is cumulative from May 2024 through May 2025.

Usage JCI PMC
Text version 170 2
PDF 69 18
Figure 0 1
Scanned page 165 5
Citation downloads 60 0
Totals 464 26
Total Views 490
(Click and drag on plot area to zoom in. Click legend items above to toggle)

Usage information is collected from two different sources: this site (JCI) and Pubmed Central (PMC). JCI information (compiled daily) shows human readership based on methods we employ to screen out robotic usage. PMC information (aggregated monthly) is also similarly screened of robotic usage.

Various methods are used to distinguish robotic usage. For example, Google automatically scans articles to add to its search index and identifies itself as robotic; other services might not clearly identify themselves as robotic, or they are new or unknown as robotic. Because this activity can be misinterpreted as human readership, data may be re-processed periodically to reflect an improved understanding of robotic activity. Because of these factors, readers should consider usage information illustrative but subject to change.

Advertisement